Last reviewed · How we verify
Drug: BufferGel® with diaphragm
BufferGel is a vaginal microbicide gel that buffers vaginal pH to create an acidic environment hostile to HIV and other sexually transmitted pathogens, used in conjunction with a diaphragm for contraceptive and prophylactic protection.
BufferGel® with diaphragm is a contraceptive gel being developed by ReProtect Inc. It has completed Phase 2 and 3 trials, demonstrating safety and efficacy. The product is not yet FDA-approved but shows promise in non-hormonal contraception.
At a glance
| Generic name | Drug: BufferGel® with diaphragm |
|---|---|
| Sponsor | ReProtect Inc |
| Drug class | Vaginal microbicide |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Sexual Health |
| Phase | Phase 2 |
Mechanism of action
BufferGel works by maintaining an acidic vaginal pH (≤3.8) through its buffering capacity, which inactivates HIV and reduces the viability of other sexually transmitted organisms. When used with a diaphragm, it provides both a physical barrier and chemical protection against pathogen transmission. The combination approach targets multiple mechanisms of infection prevention.
Approved indications
- HIV prevention in women (Phase 2)
- Contraception when used with diaphragm
Common side effects
- Vaginal irritation
- Vulvovaginal discomfort
- Genital erythema
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: BufferGel® with diaphragm CI brief — competitive landscape report
- Drug: BufferGel® with diaphragm updates RSS · CI watch RSS
- ReProtect Inc portfolio CI